Search Results - Tom Hillary

Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis by Sara Peeters, Kurt De Vlam, Hugo Boonen, Canan Güvenç, Tom Hillary

Connect to this object online.

Disease severity in moderate‐to‐severe plaque psoriasis: Results from the Belgian REDISCOVER study by Tom Hillary, Liesbeth F. E. Ghys, Fabienne Willaert, Sandra Swimberghe, Myriam Lecuyer, Pierre‐Dominique Ghislain, Joachim Morrens, Jo Lambert

Connect to this object online.

Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists by Alvaro Gonzalez-Cantero, MD, PhD, María Magdalena Constantin, MD, Annunziata Dattola, MD, Tom Hillary, MD, Elise Kleyn, MD, PhD, Nina Magnolo, MD

Connect to this object online.

The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic reviewCapsule Summary by Marie Vangilbergen, MD, Aline Stockman, MD, Axelle Van De Velde, MD, Maria Garmyn, MD, PhD, Kevin Punie, MD, PhD, Tom Hillary, MD, PhD

Connect to this object online.